Story perspectives

Study: Constipation Drug May Slow Kidney Damage in CKD

9/10/2025

30 6

Summary

Story summary

Lubiprostone, a constipation drug, may slow kidney damage in chronic kidney disease (CKD) patients by improving gut and mitochondrial health.
CKD often leads to dialysis due to significant kidney function loss.
A Phase II trial at Tohoku University involved 150 moderate CKD patients.
Results showed lubiprostone slowed kidney function decline in a dose-dependent manner versus placebo.
Future Phase 3 trials aim to validate these findings and identify treatment biomarkers.

1 of 1

Story summary

Lubiprostone, a constipation drug, may slow kidney damage in chronic kidney disease (CKD) patients by improving gut and mitochondrial health.
CKD often leads to dialysis due to significant kidney function loss.
A Phase II trial at Tohoku University involved 150 moderate CKD patients.
Results showed lubiprostone slowed kidney function decline in a dose-dependent manner versus placebo.
Future Phase 3 trials aim to validate these findings and identify treatment biomarkers.